Biopharma Money on the Move: October 7-14 – BioSpace
Posted: October 18, 2020 at 4:51 am
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Evotec
The UAE dropped a load of cash to become a 5.6% stakeholder into Germanys Evotec with $236 million worth of shares purchased by their sovereign wealth fund, Mubadala Investment Company. Not one to be left out, existing investor Novo increased its stake to 11% by throwing in another $59 million, bringing Evotecs haul to about $295 million. Evotec is a drug discovery alliance and development partnership company out of Hamburg, Germany. With revenues nearly quadrupling over the last five years and a goal of 10% yearly growth in the future, its no surprise these investors want in big. Evotec plans to use the cash to reach its goals by growing, particularly in the U.S. and Europe as they ramp up global ops.
SQZ Biotech
Allied with Roche to develop new cancer cell therapies, SQZ has turned its focus to the NYSE. With a preliminary goal of $75 million for its IPO, theyve applied for listing as SQZ. While traditional cell therapies require a depletion of the immune cells to improve efficacy, SQZ claims to avoid those limitations with a proprietary technology that, as its name touts, squeezes cells through a microfluidic chip to open the cell membrane and allow the therapeutic load inside. They also tout a huge leg up in manufacturing 24-hour turnaround in comparison with a month or more for current therapies. Plus, without the pre-conditioning to weaken immune systems, SQZs technology aims to shorten hospital stays. The IPO earnings are intended to finance their groundbreaking cancer and infectious disease research.
Galecto Biotech
Just two weeks after completing a $64 million Series D round, Galecto Biotech rounds the corner and goes after the public market, hoping to raise $100 million in its IPO. If successful, the Copenhagen-based company will have totaled over $250 million in financing in just the last two years. Galectos focus is on a wide range of fibrotic disease, with its lead project, GB0139 for idiopathic pulmonary fibrosis, currently in a Phase IIb trial. The Series D and the new funding from this IPO will go toward getting the program through to approval and commercialization.
Codiak BioSciences
After filing to go public for a second time after withdrawing in 2019, Codiak finally hit the market with an $83 million IPO, falling short of its $100 million originally sought when filed in September. The bulk of the funds will be used to advance its lead program ExoSTING through a phase study in advanced or metastatic, recurrent solid tumors, support discover and preclinical R&Dand expand its engEx technology that supports its programs. Another $10 million will go into its second program, exoIL-12, through a Phase I trial in patients with cutaneous T-cell lymphoma.
EdiGene
A Series B of $67 million takes EdiGenes track record up to $100 million raised in the last two years. The Beijing-based biotech is currently leading the gene-editing wave in China with four platforms steadily advancing. The company's top candidate is a treatment for hereditary blood disease, with the next in line being a CAR-T treatment for cancer. CEO Dong Wei hopes their T cell therapeutics can help make a higher quality, lower cost option for patients and their families.
Cedilla Therapeutics
Small molecule-focused Cedilla wraps up a $57.6 million Series B round to drug the undruggable. The funding will go into preclinical work on its first two oncology candidates, which are being kept hush hush for now. They also have about five or six oncology programs running that are years away from the clinic. In addition to the Series B, Cedilla is bringing Casdin CIO and founder Eli Casdin and Boxer senior VP Dominik Naczynski onto its board of directors.
RayzeBio
Debuting with $45 million in Series A money, biotech newbie RayzeBio is ready to defeat cancer with radiopharmaceuticals. With a vision to be the first radiopharma platform in the market, RayzeBio has seven active programs and would like to see one development candidate by the second half of 2021. Radiopharmaceuticals have intrigued the biotech sphere lately, but securing a reliable supply of therapeutic radioisotopes has been a hang up. But recently the industry has devised alternate ways to generate Actinium-225, which is the radioisotope RayzeBio is working with. This new development spurred the drive to launch RayzeBio with the intent to penetrate specific tumor targets. The fledgling biotech is now rolling up its sleeves to get to work with the goal of being first.
Priothera Limited
To get more clinical data on its highly-promising therapy for high risk AML patients, Priothera closed on a $35 million USD Series A. The company's drug mocravimod should enhance the curative potential of allogeneic hematopoietic stem cell transplantation for treating AML. Allogeneic stem cell transplant is currently the only potentially curative approach for AML patients, but has a high mortality rate. This therapy appears promising for improving survival outcomes. Priothera acquired mocravimod from KYORIN Pharmaceutical.
Ori Biotech
Ori Biotech wants to speed up the innovation of cell and gene therapies via its manufacturing platform, and this weeks $30 million Series A is certainly a step in reaching that goal. Typically, a drug discovery pipeline can take an average of a decade to get from lab to patient. Oris platform closes, automates and standardizes manufacturing for cell and gene therapy developers so the company can move its treatments from pre-clinical to scale commercially. This novel automation will reduce cost of goods and the footprint. In addition to taking its platform to the market, Ori is also expecting to double its 8-head employee count in four months, and double that again by next year.
Kanaph Therapeutics
Kanaph beefs up its initial $8 million start in 2019 with a $21 million Series B in South Korea. This round of funding will go toward expediting the clinical development of Kanaphs pipelines, chiefly its TMEkine molecules platform for immuno-oncology and bi-specific Fc fusions for the treatment of retinal disease. Preclinical studies are anticipated to be completed at the end of this year or beginning of next year, and are ready for the next steps.
Rappta Therapeutics
Novo Seeds plants its stake in emerging biotech Rappta Therapeutics in a $10.5 million Series A round. Rapptas primary focus is developing first-in-class anti-cancer drugs that work by activating protein phosphatase 2A (PP2A). The PP2A enzyme is a key tumor suppressor which has historically been tricky to target with drugs. Rappta has derived a unique understanding of the protein along with propriety tools to allow therapeutic reactivation of PP2A, which offers the potential of multiple therapies with this as the platform for a new class of anti-cancer drugs. Jeroen Bakker, Principal at Novo Seeds, will join Rapptas board. Novartis Venture Fund, Advent Life Sciences and one family office also participated in the round.
Lixte Biotechnology
Previously listed on the OTCQB, Lixte is ready to take it to Nasdaq with a $9 million offering of 1.5 million shares at a price range of $5.75 to $6.75. The NY-based biotech has developed two active series LB-100 and LB-200. The current focus is on the LB-100, which targets several types of cancer and has potential for vascular and metabolic diseases. A Phase I trial has already been completed and demonstrated antitumor activity in humans. LB-100 is now in Phase Ib/II.
Link:
Biopharma Money on the Move: October 7-14 - BioSpace
- This Pitt program is leveling up the gene therapy workforce in Pittsburgh - University of Pittsburgh - March 12th, 2024
- Opinion | Banning Gain-of-Function Research Would Do Far More Harm Than Good - Medpage Today - March 12th, 2024
- The Biggest Challenges Facing Broader Adoption of Novel Cell and Gene Therapies - Pharmaceutical Executive - March 12th, 2024
- Research and development areas of focus - Bristol Myers Squibb - March 4th, 2024
- Overcoming the challenges of gene therapy - Drug Discovery News - March 4th, 2024
- Breakthrough Gene Therapy for LHON: Vision Restoration in Focus at Medical Conference - BNN Breaking - March 4th, 2024
- Revolutionizing Healthcare: Global Gene Therapy Market Surges to US$ 3.44 Billion by 2022 As Revealed In Ne... - WhaTech - March 4th, 2024
- Looking to the future of clinical trials: Gene therapy, precision medicine, and the ongoing quest for rare disease solutions - pharmaphorum - March 4th, 2024
- Complement system response to AAV vector gene therapy - EurekAlert - February 23rd, 2024
- 10 gene therapy companies you should know about - Labiotech.eu - February 23rd, 2024
- Fetal surgery expert Tippi MacKenzie shifts to in-utero gene therapy - STAT - February 23rd, 2024
- Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age ... - Business Wire - February 23rd, 2024
- Combatting HIV using gene therapy - Drug Target Review - February 23rd, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 23rd, 2024
- Global Advanced Therapy Medicinal Products CDMO Market Analysis Report 2024-2030: : Increasing Investment and ... - Yahoo Finance UK - February 23rd, 2024
- 2023 gene therapy research STAR Grant winners announced - Pacific Biosciences - February 13th, 2024
- Lifetime Cost of DEB Gene Therapy Could Be $15-$22 Million - Medscape - February 13th, 2024
- 5 Things Youll Learn in Frederick Community Colleges New Cell and Gene Therapy Essentials Certificate ... - BioBuzz - February 13th, 2024
- Regenxbios investigational gene therapy shows promise in Hunter syndrome - PMLiVE - February 13th, 2024
- Topical Gene Therapy Effective in Treating Debilitating Eye Condition - InventUM - University of Miami - February 13th, 2024
- Bayer Says First Patient Randomized In Askbio Phase II Gene Therapy Trial - XM - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Realistic Expectations, Limitations With Gene Therapy for Parkinson Disease: Ignacio Mata, PhD - Neurology Live - February 5th, 2024
- Gene-Based Therapy May Slow Development of Life-Threatening Heart Condition - NYU Langone Health - February 5th, 2024
- After Promising Early Efficacy, Eli Lilly Eager to Study Hearing Loss Gene Therapy in More Children - precisionmedicineonline.com - February 5th, 2024
- Gene therapy hailed as medical magic wand for hereditary swelling disorder - The Guardian - February 5th, 2024
- France Approves Gene Therapy Clinical Trial to Treat Hearing Loss in Children - The Hearing Review - February 5th, 2024
- Early Trial Success for Inherited Deafness Gene-Therapy - RegMedNet - February 5th, 2024
- Can gene therapy be the key to restoring hearing loss? - Labiotech.eu - February 5th, 2024
- Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum ... - Business Wire - February 5th, 2024
- FDA inspection clears Abeona's gene therapy BLA By Investing.com - Investing.com - February 5th, 2024
- Hearing Restored in Deaf Children in Gene Therapy Clinical Trial - Securities.io - February 5th, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - The Associated Press - January 28th, 2024
- Children with genetic deafness have hearing restored with gene therapy: Study - ABC News - January 28th, 2024
- Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at ... - Investors | Eli Lilly and... - January 28th, 2024
- UChicago Medicine among the first in the country to offer newly approved sickle cell gene therapies - UChicago Medicine - January 28th, 2024
- Gene Therapy Allows an 11-Year-Old Boy to Hear for the First Time - The New York Times - January 28th, 2024
- Gene therapy restores hearing in children with hereditary deafness - EurekAlert - January 28th, 2024
- Experimental gene therapy helps treat kids with inherited hearing loss - CBS News - January 28th, 2024
- Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss - PR Newswire - January 28th, 2024
- Gene Therapy Brings Hearing to Kids With Congenital Deafness - U.S. News & World Report - January 28th, 2024
- Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness - Technology Networks - January 28th, 2024
- Cell Therapies on Ice: Seven Trends in Cryopreservation To Enable Cell and Gene Therapy Research - Technology Networks - January 28th, 2024
- Gene Therapy Brings Hearing to Kids With Congenital Deafness - HealthDay - January 28th, 2024
- Gene therapies restore hearing in several kids with inherited deafness - Livescience.com - January 28th, 2024
- 11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough - IFLScience - January 28th, 2024
- Innovative Gene Therapy Restores Hearing In Deaf Child, Offering Potential Cure - Study Finds - January 28th, 2024
- Sound of Success, Gene Therapy Breakthrough Grants Hearing to Deaf Children in China-Harvard Study - Hoodline - January 28th, 2024
- Perspectives in FTD Research Webinar: Gene Therapy for FTD -- What Do I Need to Know? | AFTD - AFTD - January 20th, 2024
- UK leads the way in cell and gene therapy - Research Professional News - January 20th, 2024
- Charles River's (CRL) New Launch to Boost Gene Therapy Programs - Yahoo Finance - January 20th, 2024
- UK maintains status as an attractive destination for advanced therapy clinical trials - BioPharma-Reporter.com - January 20th, 2024
- Understanding the impact of AI on the advancement of gene therapy development - pharmaphorum - January 20th, 2024
- Gene therapy TSHA-102 delivered to 1st child in REVEAL trial - Rett Syndrome News - January 20th, 2024
- AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032 ... - PR Newswire - January 20th, 2024
- Family pins hopes on gene therapy - The Recorder and Times - January 20th, 2024
- Arbor, 4DMT partner on new gene therapies in ALS, other diseases - ALS News Today - January 11th, 2024
- The year of gene therapy? FDA's Marks calls for solutions to regulatory, manufacturing challenges - BioWorld Online - January 11th, 2024
- Gene Therapy Approvals Expected to Ramp Up in 2024 Amid Manufacturing, Cost Challenges - BioSpace - January 11th, 2024
- Turning On Gene Therapy with the pA Regulator - RegMedNet - January 11th, 2024
- Revolutionizing Healthcare: Gene Therapy Market Projected to Reach USD 46.5 billion by 2030 at a 22. - PharmiWeb.com - January 11th, 2024
- Regeneron CEO Reveals the Game-Changing Potential of Gene Therapy in Biotech! - BioTecNika - January 11th, 2024
- Bayer's AskBio checks off another early win for gene therapy platform with Parkinson's safety data - FierceBiotech - January 11th, 2024
- Are Rare Brain Diseases the Next Commercial Frontier for Gene Therapy? - MedCity News - January 3rd, 2024
- Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration - Genetic Engineering & Biotechnology News - January 3rd, 2024
- Novel switch turns genes on/off on cue, a promising step toward safer gene therapy - Phys.org - January 3rd, 2024
- Which Therapeutic Areas Experts Think Will Gain Traction In 2024 - Clinical Leader - January 3rd, 2024
- Voyager Therapeutics and Novartis Announce Major Licensing Deal in Gene Therapy Field - Medriva - January 3rd, 2024
- We Are About to Enter the Golden Age of Gene Therapy - Inverse - January 3rd, 2024
- Revolutionizing Gene Therapy: Baylor Researchers Develop RNA-Based Switch for Therapeutic Protein Control - BNN Breaking - January 3rd, 2024
- Casgevy and Lyfgenia: Two Gene Therapies Approved for Sickle Cell Disease - Yale Medicine - December 25th, 2023
- Top story: Family connects with researchers behind Canavan gene therapy - UMass Medical School - December 25th, 2023
- Excision Bio Seeks to Suppress HIV Replication With CRISPR Gene Therapy - AJMC.com Managed Markets Network - December 25th, 2023
- Hemgenix Gene Therapy Shows Long-Term Efficacy, Safety in Hemophilia B Patients - Managed Healthcare Executive - December 25th, 2023
- The missing piece of the puzzle - EUobserver - December 25th, 2023
- Brace yourselves for these trends in clinical research in 2024 - Labiotech.eu - December 25th, 2023
- RegMedNet's 2023 remix: top content of the year - RegMedNet - December 25th, 2023
- BU Researchers Helped Develop the First FDA-Approved Gene Therapies to Treat Sickle Cell Disease - Boston University - December 16th, 2023
- Research discovers that mice possess a natural gene therapy system - Phys.org - December 16th, 2023
- Cell- and gene-therapy hub bound for Lake Success; New York to invest up to $150 million - Newsday - December 16th, 2023